Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label Study to Evaluate 3 Salvage Regimens in HIV-Infected Subjects Experiencing Virologic Failure on an Initial HAART Regimen Containing Nelfinavir

NCT00006326 is registered in ClinicalTrials.gov with Agouron Pharmaceuticals as lead sponsor.

NCT NCT00006326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label Study to Evaluate 3 Salvage Regimens in HIV-Infected Subjects Experiencing Virologic Failure on an Initial HAART Regimen Containing Nelfinavir
Lead sponsor
Agouron Pharmaceuticals
Phase
Not applicable
Overall status
Terminated
Start date
August 31, 2000
Completion date
Not reported
Enrollment
60
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections